Catherine Skari

FDA APPROVES AQVESME™ (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia

This regulatory decision marks a landmark milestone in the management of thalassaemia, as AQVESME is now the first and only…

PUTTING PATIENTS FIRST IN CLINICAL RESEARCH | New EU Recommendations to Reduce Trials Bureaucracy

As Prof. Martin Dreyling, Chair of the Coalition for Reducing Bureaucracy, explains: “The current safety requirements for investigators are disproportionately…

EU AGREES LANDMARK REFORM OF PHARMACEUTICAL LEGISLATION | What It Means for Patients and Public Health

 This milestone agreement — part of what has been referred to as the “pharma package” — was negotiated between the…

National Thalassemia Registry: A 30-year Journey of implementing Carrier Screening in Singapore

Introduction Haemoglobinopathies, which include thalassemia and structural haemoglobin variants, are the most common inherited disease affecting an estimated 20% of the world’s population.…

1st TIF NURSING WORKSHOP ON HAEMOGLOBINOPATHIES | 29-30 November 2025

1st TIF NURSING WORKSHOP ON HAEMOGLOBINOPATHIES | 29-30 November 2025

📌 Workshop Title: 1st TIF Nursing Workshop on Haemoglobinopathies 📌 Date & Venue: Saturday & Sunday, 29-30 November 2025 |…

TOPICS IN FOCUS SERIES | Guidelines for the Management of Thalassaemia Syndromes

Each booklet focuses on a specific aspect of the updated guidelines for transfusion-dependent thalassaemia (TDT), non-transfusion-dependent β-thalassaemia (NTDT), and α-thalassaemia,…

ANNUAL REPORT 2024 | A Year of Resilience and Progress

It is a privilege to present the Federation’s Annual Report for 2024, capturing a year defined by resilience, innovation, and…

SICKLE CELL DISEASE | Inflammation during Menstrual Cycle May Trigger Pain Crises

SCD is a genetic disorder in which red blood cells can become abnormally shaped (“sickle”), leading to blockages in blood…